Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
bIAP in Patients Undergoing Combined AVR and CABG
NCT01144611Phase 3Completed
- Sponsor
- Alloksys Life Sciences
- Start
- Apr 2010
- Primary completion
- Dec 2013
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in inflammation and organ dysfunction comparing bIAP Arm with Placebo Arm (2 arms). Primary endpoint: Tumor Necrosis Factor-alpha at 5 days. Started Apr 2010; status: completed.
02
Drugs
bovine intestinal alkaline phosphatase
03
Conditions
inflammationorgan dysfunction
Beyond the preview
Go deeper on NCT01144611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01144611.